Genmab A/S (NASDAQ:GMAB) Price Target Raised to $50.00

Genmab A/S (NASDAQ:GMAB) had its price objective hoisted by HC Wainwright from $40.00 to $50.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.48 EPS, Q4 2026 earnings at $0.42 EPS, FY2026 earnings at $1.45 EPS and FY2027 earnings at $1.59 EPS.

Several other equities research analysts also recently commented on the company. Guggenheim raised their target price on Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and boosted their target price for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Genmab A/S Stock Up 2.8%

Shares of NASDAQ GMAB opened at $37.07 on Wednesday. The stock has a fifty day moving average price of $33.61 and a 200 day moving average price of $29.36. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $40.17. The company has a market cap of $23.13 billion, a P/E ratio of 29.19, a P/E/G ratio of 1.67 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Research analysts anticipate that Genmab A/S will post 1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership grew its stake in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after purchasing an additional 921,700 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Quantinno Capital Management LP boosted its stake in shares of Genmab A/S by 14.4% during the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock valued at $7,579,000 after buying an additional 35,588 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Genmab A/S by 1.8% during the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock valued at $4,029,000 after buying an additional 2,637 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.